SCHEMBL4930754

SCHEMBL4930754

Cc1cc(=O)oc2cccc(O)c12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.64
HSD17B10 Q99714 4/20 0.64
HPGD P15428 3/20 0.64
CA9 Q16790 3/20 0.64
CYP3A4 P08684 3/20 0.64
TSHR P16473 3/20 0.64
CASP1 P29466 2/20 0.64
CASP7 P55210 2/20 0.64
HTT P42858 2/20 0.54
MCL1 Q07820 4/20 0.53
KDM4E B2RXH2 3/20 0.53
AKR1B1 P15121 2/20 0.53
THRB P10828 1/20 0.53
ATM Q13315 1/20 0.53
GAA P10253 3/20 0.50
CA12 O43570 2/20 0.50
CYP1A2 P05177 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
AR P10275 2/20 0.50
LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5346812 0.85 ALDH1A1 (0.59) ALDH1A1HSD17B10HPGDCA9CYP3A4
SCHEMBL15842423 0.82 KDM4E (0.53) ALDH1A1HSD17B10HPGDCA9CYP3A4
SCHEMBL5114485 0.82 CA9 (0.60) ALDH1A1HSD17B10HPGDCA9CYP3A4
SCHEMBL10847397 0.79 MEN1 (0.54) ALDH1A1HSD17B10HPGDCA9CYP3A4
SCHEMBL9160367 0.79 ALDH1A1 (0.64) ALDH1A1HSD17B10HPGDCA9CASP1
SCHEMBL4922420 0.78 NQO1 (0.52) ALDH1A1HSD17B10HPGDCA9CYP3A4
SCHEMBL10794104 0.78 CA12 (0.50) ALDH1A1HSD17B10HPGDCA9CYP3A4
SCHEMBL12457526 0.78 ALDH1A1 (0.74) ALDH1A1HSD17B10HPGDCA9CYP3A4
SCHEMBL10848826 0.78 AR (0.50) ALDH1A1HSD17B10HPGDCA9CYP3A4
5,7-Dihydroxy-4-Methylcoumarin SCHEMBL403833 0.78 ALDH1A1 (1.00) ALDH1A1HSD17B10HPGDCA9CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-21 US disclosed
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2022-02-24 US disclosed
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2021-12-14 US disclosed
US-20200360379-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2020-11-19 US disclosed
US-20190192516-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2019-06-27 US disclosed
US-10265316-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUCTICS LIMITED (GB) 2019-04-23 US disclosed
US-20170273981-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2017-09-28 US disclosed
US-20170273981-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2017-09-28 US disclosed
US-9620363-B2 Underlayer film-forming composition and pattern forming process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2017-04-11 US disclosed
US-9620363-B2 Underlayer film-forming composition and pattern forming process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2017-04-11 US disclosed
US-20080194522-A1 Development of Fluorogenic Substrates For Monoamine Oxidases (Mao-A and Mao-B) TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE 2008-08-14 US disclosed
US-20080194522-A1 Development of Fluorogenic Substrates For Monoamine Oxidases (Mao-A and Mao-B) TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE 2008-08-14 US disclosed
US-20080194522-A1 Development of Fluorogenic Substrates For Monoamine Oxidases (Mao-A and Mao-B) TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE 2008-08-14 US disclosed
CN-1027268-C Process for preparing benzopyrone-beta-D-thioxylosides FOURNIER IND & SANTE (FR) 1995-01-04 CN disclosed
EP-0421829-B1 Benzopyranone-beta-D-thioxylosides, method for their preparation and their use FOURNIER IND & SANTE (FR) 1994-11-09 EP disclosed
US-5169838-A Anticoagulants FOURNIER INDUSTRIE ET SANTE (FR) 1992-12-08 US disclosed
EP-0421829-A1 Benzopyranone-beta-D-thioxylosides, method for their preparation and their use FOURNIER INDUSTRIE ET SANTE (FR) 1991-04-10 EP disclosed
CN-1050544-A Novel benzopyrone-β-D-sulfo-xyloside, their preparation method and the application in treatment thereof FOURNIER IND & SANTE (FR) 1991-04-10 CN disclosed
US-4618622-A ANTIDEPRESSANTS, ANTIALLERGENS BASF AKTIENGESELLSCHAFT (DE) 1986-10-21 US disclosed
EP-0111746-A2 Sulfonic-acid esters of hydroxycoumarines, their preparation and medicines containing them BASF Aktiengesellschaft (DE) 1984-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190192516-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 ALDH1A1 1966/4885HSD17B10 2069/4885HPGD 734/4885
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 ALDH1A1 1966/4885HSD17B10 2069/4885HPGD 734/4885
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 ALDH1A1 1966/4885HSD17B10 2069/4885HPGD 734/4885
US-20080194522-A1 Development of Fluorogenic Substrates For Monoamine Oxidases (Mao-A and Mao-B) MAOA, MAOB, COMT ALDH1A1 181/4885HSD17B10 336/4885HPGD 296/4885
US-20200360379-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 ALDH1A1 1966/4885HSD17B10 2069/4885HPGD 734/4885
US-20170273981-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNA3, KCND3, KCNN3 ALDH1A1 1789/4885HSD17B10 2091/4885HPGD 834/4885
US-10265316-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNA3, KCND3, KCNN3 ALDH1A1 1789/4885HSD17B10 2091/4885HPGD 834/4885
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 ALDH1A1 1966/4885HSD17B10 2069/4885HPGD 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.